Filtered By:
Vaccination: Varicella-Zoster Virus Vaccine

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 2327 results found since Jan 2013.

Herpes zoster prevention: A difficult problem to solve.
Abstract The clinical relevance of herpes zoster (HZ) and its increased incidence in recent years has prompted a search for more effective measures of prevention and therapy. A number of vaccines has been developed. For two of them, the live attenuated HZ vaccine (LAHZV) and the adjuvanted recombinant subunit HZ vaccine (SUHZV), data regarding immunogenicity, efficacy, safety and reactogenicity have been collected. This information allows us to draw some conclusions about what can be expected from their use and what is still required to definitively solve the problem of HZ prevention. The currently licensed vaccin...
Source: Vaccine - August 4, 2017 Category: Allergy & Immunology Authors: Esposito S, Principi N Tags: Vaccine Source Type: research

Epidemiology, treatment and prevention of herpes zoster: A comprehensive review
This study mainly focuses on herpes zoster using articles and reviews from PubMed, Embase, Cochrane library, and a manual search from Google Scholar. We cover the incidence of herpes zoster, gender distribution, seasonal and regional distribution of herpes zoster, incidence of herpes zoster among immunocompromised individuals, incidence of post-herpetic neuralgia following a zoster infection, complications, management, and prevention of herpes zoster and post-herpetic neuralgia.
Source: Indian Journal of Dermatology, Venereology and Leprology - April 13, 2018 Category: Dermatology Authors: Elsam Koshy Lu Mengting Hanasha Kumar Wu Jianbo Source Type: research

A standardized approach to the evaluation of antivirals against DNA viruses: Orthopox-, adeno-, and herpesviruses
Publication date: Available online 1 October 2018Source: Antiviral ResearchAuthor(s): Caroll B. Hartline, Kathy A. Keith, Jessica Eagar, Emma A. Harden, Terry L. Bowlin, Mark N. PrichardAbstractThe search for new compounds with a broad spectrum of antiviral activity is important and requires the evaluation of many compounds against several distinct viruses. Researchers attempting to develop new antiviral therapies for DNA virus infections currently use a variety of cell lines, assay conditions and measurement methods to determine in vitro drug efficacy, making it difficult to compare results from within the same laboratory...
Source: Antiviral Therapy - October 4, 2018 Category: Virology Source Type: research

A standardized approach to the evaluation of antivirals against DNA viruses: Orthopox-, adeno-, and herpesviruses.
Abstract The search for new compounds with a broad spectrum of antiviral activity is important and requires the evaluation of many compounds against several distinct viruses. Researchers attempting to develop new antiviral therapies for DNA virus infections currently use a variety of cell lines, assay conditions and measurement methods to determine in vitro drug efficacy, making it difficult to compare results from within the same laboratory as well as between laboratories. In this paper we describe a common assay platform designed to facilitate the parallel evaluation of antiviral activity against herpes simplex ...
Source: Antiviral Research - October 1, 2018 Category: Virology Authors: Hartline CB, Keith KA, Eagar J, Harden EA, Bowlin TL, Prichard MN Tags: Antiviral Res Source Type: research

Evidence Based Recommendations for Supportive Care in Multiple Myeloma
Conclusion:Along with anti-myeloma chemotherapy therapy, management of complications (anemia, infections, renal insufficiency) and other associated symptoms is necessary to improve the quality of life.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Qureshi, A., Tariq, M. J., Shah, Z., Abu Zar, M., Aslam, S., Rafae, A., Malik, M. N., Kamal, A., Jose, J. A., Selene, I. I., Shafqat, M., Jamil, F., Durer, S., Durer, C., Anwer, F. Tags: 653. Myeloma: Therapy, excluding Transplantation: Poster I Source Type: research

Interventions to improve vaccine acceptance among rheumatoid arthritis patients: a systematic review
ConclusionsInterventions to enhance vaccine uptake in RA focused almost exclusively on improving provider prescription of vaccines using reminder-type interventions. Although effective in improving vaccination rates, those studies used heterogeneous interventions and behavior change techniques. Few studies measured provider prescribing behavior as an outcome. Future studies targeting providers should measure relevant provided-related outcomes and their impact on patient outcomes, to determine overall efficacy.
Source: Clinical Rheumatology - January 15, 2019 Category: Rheumatology Source Type: research

Update in Herpes Zoster Prevention and the Role of Dermatologists
Authors: Feli KH, Ediale CE, McMichael AJ Abstract A recombinant vaccine (HZ/su) was approved in 2017 to prevent herpes zoster (HZ) infection and associated sequelae with greater efficacy and safety than its live precursor. Though dermatologists regularly encounter patients with HZ infection, recommendation of vaccination by dermatologists and other physicians has been minimal in past years. Overall patient awareness and utilization of the HZ vaccines has subsequently been low. While HZ/su touts several improvements over the live vaccine, dermatologists still face obstacles to vaccine recommendation and administrat...
Source: Journal of Drugs in Dermatology - January 27, 2019 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Composition and mode of action of adjuvants in licensed viral vaccines.
In this report, adjuvants that are components of vaccines licensed in the EU will be presented and their mode of action will be discussed.Aluminum salts have been used for almost a century as vaccine adjuvants. In recent years numerous novel immune-stimulating substances have been developed and integrated into licensed human vaccines. These novel adjuvants are not only intended to generally increase the vaccine-induced antibody titers, but are also aimed at modulating and triggering a specific immune response. The search for innovative adjuvants was considerably stimulated during development of pandemic influenza vaccine...
Source: Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz - March 3, 2019 Category: International Medicine & Public Health Authors: Wagner R, Hildt E Tags: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Source Type: research

Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions.
Authors: Wu KK, Lee MP, Lee EB, Wu JJ Abstract Psoriasis is a chronic inflammatory skin disease that has been associated with a significantly higher risk of herpes zoster (HZ). Several newer biologics such as secukinumab, ixekizumab, and brodalumab inhibit IL-17 and have been highly effective for treatment of psoriasis. However, adverse events related to the immunosuppressive properties of these biologics have been observed. This review aims to synthesize and evaluate the literature investigating the risk of HZ in patients treated with IL-17 inhibitors, with a focus on psoriasis patients. Clinical trials, cohort st...
Source: Journal of Dermatological Treatment - March 24, 2019 Category: Dermatology Tags: J Dermatolog Treat Source Type: research

Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review
ConclusionThe most advanced phase III clinical applications led to the development of two vaccines containing QS-21 as part of AS, the Herpes Zoster vaccine (HZ/su) (ShingrixTM) which received a license in 2017 from the FDA and a marketing authorization in EU in 2018 and the RTS,S/AS01 vaccine (MosquirixTM) against malaria which was approved by the EMA in 2015 for further implementation in Sub Saharan countries for routine use.Graphical abstract
Source: Phytomedicine - April 1, 2019 Category: Drugs & Pharmacology Source Type: research

Vaccines for preventing herpes zoster in older adults.
CONCLUSIONS: LZV and RZV are effective in preventing herpes zoster disease for up to three years (the main studies did not follow participants for more than three years). To date, there are no data to recommend revaccination after receiving the basic schedule for each type of vaccine. Both vaccines produce systemic and injection site adverse events of mild to moderate intensity. PMID: 31696946 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - November 6, 2019 Category: General Medicine Authors: Gagliardi AM, Andriolo BN, Torloni MR, Soares BG, de Oliveira Gomes J, Andriolo RB, Canteiro Cruz E Tags: Cochrane Database Syst Rev Source Type: research

Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series
In conclusion, it is necessary to pay attention to therapies acting on B lymphocytes as they could influence the antibody titer and efficacy of vaccination making the search for other markers of vaccine efficacy desirable such as cell-mediated immunity with proliferation and induction of memory T lymphocytes in response to viral glycoproteins.
Source: Multiple Sclerosis and Related Disorders - January 21, 2020 Category: Neurology Source Type: research

Emergence of varicella-zoster virus resistance to acyclovir: epidemiology, prevention, and treatment
Expert Rev Anti Infect Ther. 2021 Apr 14. doi: 10.1080/14787210.2021.1917992. Online ahead of print.ABSTRACTINTRODUCTION: Acyclovir has led to the development of successful systemic therapy for herpes simplex virus and varicella-zoster virus (VZV) infection, and the use of valacyclovir and famciclovir has improved treatment. Additionally, the use of a helicase-primase (HP) inhibitor (HPI), amenamevir, is changing the treatment of herpes zoster (HZ).AREA COVERED: VZV infection is prevented by vaccines and is treated with antiviral agents. Acyclovir and penciclovir are phosphorylated by viral thymidine kinase and work as cha...
Source: Expert Review of Anti-Infective Therapy - April 15, 2021 Category: Infectious Diseases Authors: Kimiyasu Shiraki Masaya Takemoto Tohru Daikoku Source Type: research